Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
NCT ID: NCT06205602
Last Updated: 2025-01-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
135 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-01-17
Study Completion Date
2029-02-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body and can start multiplying when ART is stopped.
This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance that the body makes in response to an infection. The antibodies being used in this study were made in a laboratory and were designed to attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV.
The main purpose of this study is to see if the study drugs affect the level of HIV that remains in the blood cells while taking ART and the level of HIV in the blood after discontinuing taking ART. The study will also see if it is safe to give people these antibodies and if they cause any side effects.
This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance that the body makes in response to an infection. The antibodies being used in this study were made in a laboratory and were designed to attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV.
The main purpose of this study is to see if the study drugs affect the level of HIV that remains in the blood cells while taking ART and the level of HIV in the blood after discontinuing taking ART. The study will also see if it is safe to give people these antibodies and if they cause any side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Acute HIV Infection to Preserve Immune Function
NCT00055094
HIV Infections
COMPLETED
Response to Standard HIV Treatment in Bamako, Mali
NCT00703404
HIV Infections
COMPLETED
Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials
NCT00183287
HIV Infections
COMPLETED
Analysis of HIV-1 Replication During Antiretroviral Therapy
NCT00767312
HIV
ENROLLING_BY_INVITATION
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans
NCT02154035
HIV
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV-1-infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Caregivers
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Broadly neutralizing antibodies (bNAbs) infusions with antiretroviral therapy (ART)
Group Type
ACTIVE_COMPARATOR
3BNC117-LS
Intervention Type
DRUG
30 mg/kg to be administered via IV at Step 1 (Day 1)
10-1074-LS
Intervention Type
DRUG
10 mg/kg to be administered intravenously at Step 1 (Day 1)
Placebo infusions with ART
Group Type
PLACEBO_COMPARATOR
Placebo for 3BNC117-LS
Intervention Type
DRUG
0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
Placebo for 10-1074-LS
Intervention Type
DRUG
0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3BNC117-LS
30 mg/kg to be administered via IV at Step 1 (Day 1)
Intervention Type
DRUG
10-1074-LS
10 mg/kg to be administered intravenously at Step 1 (Day 1)
Intervention Type
DRUG
Placebo for 3BNC117-LS
0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
Intervention Type
DRUG
Placebo for 10-1074-LS
0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study Step 1 entry AND Confirmed by one of the following:
* A second antibody test from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used)
* HIV-1 antigen
* Plasma HIV-1 RNA viral load or
* A licensed Western blot
NOTE: The term "licensed" refers to a US FDA or DAIDS Clinical Laboratory Oversight (DCLOT) approved test.
WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
* ART-naïve \[NOTE: Prior use of PrEP or PEP is allowed, except use of long-acting ARVs (e.g., cabotegravir, rilpivirine) within the last 24 months.\]
* CD4+ T cell count \>200 cells/mm3 obtained within 28 days prior to study entry at any Network-approved non-US laboratory that is (IQA) certified.
* Plasma HIV-1 RNA \>1000 copies/mL obtained within 28 days prior to study entry performed at any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance (EQA) programs.
* For study candidates of child-bearing potential, negative urine or serum pregnancy test within 72 hours prior to study entry by any Network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate EQA programs.
\[NOTE A: Persons who are of child-bearing potential are individuals who have not been post-menopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, and who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy, tubal ligation, or bilateral salpingectomy.\] \[NOTE B: Acceptable documentation of hysterectomy and bilateral oophorectomy, tubal ligation, and tubal micro-inserts are written documentation or oral communication from a clinician or clinician's staff documented in source documents (physician report/letter, operative report or other source documentation in the patient record, discharge summary, laboratory report, etc.). Participant-reported history is acceptable for documentation of menopause.\]
* Persons of child-bearing potential who are able to become pregnant must agree to use two methods of contraception, if participating in sexual activity that could lead to pregnancy. One contraceptive method must be from the list of highly effective methods listed below. The second method of contraception must be a barrier method or abstinence. Both methods of contraception must be used during Step 1. The two effective forms of birth control have to be used for 10 days before receiving the first study drug infusion, for at least 12 months after the product infusion, and until ART is reinitiated and viral suppression is achieved.
Acceptable methods of contraception include:
* Contraceptive subdermal implant
* Intrauterine device or intrauterine system
* Combined estrogen and progestogen oral contraceptive
* Injectable progestogen
* Contraceptive vaginal ring
* Percutaneous contraceptive patches
* Partner sterilization with documentation of azoospermia prior to the participant's entry into the study, and this individual is the sole partner for that participant.
\[NOTE: Documentation of partner sterility can come from the site personnel's review of participant's medical records, medical examination and/or semen analysis, or medical history interview provided by the participant or the partner. Self-reported documentation of reproductive potential should be entered in the source documents.\]
* Individuals engaging in sexual activity that could lead to their partner becoming pregnant must agree to use a barrier method of contraception to avoid pregnancy in a spouse or partner of reproductive potential. The barrier method must be used to prevent partner pregnancy during Step 1 and for at least 12 months after the product infusion.
* Ability and willingness to use a barrier protection or abstinence from sexual intercourse during Step 1 until viral suppression is achieved, during the ATI period (Steps 2-3), and until plasma HIV-1 RNA is less than limit of detection after ART restart (Step 4) with partners without HIV or whose HIV serostatus is unknown in order to prevent HIV transmission to sexual partners.
* Ability and willingness to initiate ART at enrollment.
* Ability and willingness to participate in scheduled study visits, including ATI per the SOE.
* Ability and willingness to provide informed consent.
* Documented negative hepatitis B virus (HBV) surface antigen (HBsAg) obtained within 16 weeks prior to Step 2 registration by any Network-approved non-US laboratory that operates in accordance with GCLP and participates in appropriate EQA programs.
* Documented negative HCV antibody (anti-HCV), negative HCV RNA PCR, or negative HCV antigen obtained within 16 weeks prior to Step 2 registration by any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate EQA programs.
* Participants diagnosed with a bacterial sexually transmitted infection (STI) must have initiated treatment prior to Step 2 entry.
* Receipt of both bNAb infusions or placebo infusions during Step 1.
* HIV-1 RNA \<200 copies/mL obtained within 6 weeks prior to Step 2 registration at any Network-approved non-US laboratory that is VQA certified.
* CD4+ T cell count ≥450 cells/mm3 obtained within 6 weeks prior to Step 2 registration at any Network-approved non-US laboratory that is IQA certified.
* For participants of child-bearing potential, negative serum or urine pregnancy test within 48 hours prior to Step 2 entry at any Network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate EQA programs.
* Ability and willingness to use a barrier method of contraception or abstinence from sexual intercourse during Steps 2 and 3, and until plasma HIV-1 RNA is less than limit of detection, with all partners who are without HIV or whose serostatus is unknown in order to prevent HIV transmission to sexual partners.
* Ability and willingness to stop ART.
* Has not met ART restart criteria.
* Completion of protocol Step 2.
* Willing to continue ATI.
* Met ART restart criteria (section 3.0) during Step 2 or Step 3 OR Completed Step 3 and is not enrolling to ACTG A5385.
* A second antibody test from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used)
* HIV-1 antigen
* Plasma HIV-1 RNA viral load or
* A licensed Western blot
NOTE: The term "licensed" refers to a US FDA or DAIDS Clinical Laboratory Oversight (DCLOT) approved test.
WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
* ART-naïve \[NOTE: Prior use of PrEP or PEP is allowed, except use of long-acting ARVs (e.g., cabotegravir, rilpivirine) within the last 24 months.\]
* CD4+ T cell count \>200 cells/mm3 obtained within 28 days prior to study entry at any Network-approved non-US laboratory that is (IQA) certified.
* Plasma HIV-1 RNA \>1000 copies/mL obtained within 28 days prior to study entry performed at any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance (EQA) programs.
* For study candidates of child-bearing potential, negative urine or serum pregnancy test within 72 hours prior to study entry by any Network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate EQA programs.
\[NOTE A: Persons who are of child-bearing potential are individuals who have not been post-menopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, and who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy, tubal ligation, or bilateral salpingectomy.\] \[NOTE B: Acceptable documentation of hysterectomy and bilateral oophorectomy, tubal ligation, and tubal micro-inserts are written documentation or oral communication from a clinician or clinician's staff documented in source documents (physician report/letter, operative report or other source documentation in the patient record, discharge summary, laboratory report, etc.). Participant-reported history is acceptable for documentation of menopause.\]
* Persons of child-bearing potential who are able to become pregnant must agree to use two methods of contraception, if participating in sexual activity that could lead to pregnancy. One contraceptive method must be from the list of highly effective methods listed below. The second method of contraception must be a barrier method or abstinence. Both methods of contraception must be used during Step 1. The two effective forms of birth control have to be used for 10 days before receiving the first study drug infusion, for at least 12 months after the product infusion, and until ART is reinitiated and viral suppression is achieved.
Acceptable methods of contraception include:
* Contraceptive subdermal implant
* Intrauterine device or intrauterine system
* Combined estrogen and progestogen oral contraceptive
* Injectable progestogen
* Contraceptive vaginal ring
* Percutaneous contraceptive patches
* Partner sterilization with documentation of azoospermia prior to the participant's entry into the study, and this individual is the sole partner for that participant.
\[NOTE: Documentation of partner sterility can come from the site personnel's review of participant's medical records, medical examination and/or semen analysis, or medical history interview provided by the participant or the partner. Self-reported documentation of reproductive potential should be entered in the source documents.\]
* Individuals engaging in sexual activity that could lead to their partner becoming pregnant must agree to use a barrier method of contraception to avoid pregnancy in a spouse or partner of reproductive potential. The barrier method must be used to prevent partner pregnancy during Step 1 and for at least 12 months after the product infusion.
* Ability and willingness to use a barrier protection or abstinence from sexual intercourse during Step 1 until viral suppression is achieved, during the ATI period (Steps 2-3), and until plasma HIV-1 RNA is less than limit of detection after ART restart (Step 4) with partners without HIV or whose HIV serostatus is unknown in order to prevent HIV transmission to sexual partners.
* Ability and willingness to initiate ART at enrollment.
* Ability and willingness to participate in scheduled study visits, including ATI per the SOE.
* Ability and willingness to provide informed consent.
* Documented negative hepatitis B virus (HBV) surface antigen (HBsAg) obtained within 16 weeks prior to Step 2 registration by any Network-approved non-US laboratory that operates in accordance with GCLP and participates in appropriate EQA programs.
* Documented negative HCV antibody (anti-HCV), negative HCV RNA PCR, or negative HCV antigen obtained within 16 weeks prior to Step 2 registration by any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate EQA programs.
* Participants diagnosed with a bacterial sexually transmitted infection (STI) must have initiated treatment prior to Step 2 entry.
* Receipt of both bNAb infusions or placebo infusions during Step 1.
* HIV-1 RNA \<200 copies/mL obtained within 6 weeks prior to Step 2 registration at any Network-approved non-US laboratory that is VQA certified.
* CD4+ T cell count ≥450 cells/mm3 obtained within 6 weeks prior to Step 2 registration at any Network-approved non-US laboratory that is IQA certified.
* For participants of child-bearing potential, negative serum or urine pregnancy test within 48 hours prior to Step 2 entry at any Network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate EQA programs.
* Ability and willingness to use a barrier method of contraception or abstinence from sexual intercourse during Steps 2 and 3, and until plasma HIV-1 RNA is less than limit of detection, with all partners who are without HIV or whose serostatus is unknown in order to prevent HIV transmission to sexual partners.
* Ability and willingness to stop ART.
* Has not met ART restart criteria.
* Completion of protocol Step 2.
* Willing to continue ATI.
* Met ART restart criteria (section 3.0) during Step 2 or Step 3 OR Completed Step 3 and is not enrolling to ACTG A5385.
Exclusion Criteria
* Any clinically significant acute or chronic medical condition, other than HIV, that in the opinion of the investigator would preclude safe participation in the study or interfere with the validity of study results.
* Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months. \[NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) are not exclusionary.\]
* History of AIDS-defining illness within 3 years prior to enrollment.
* History of systemic corticosteroids (e.g., an equivalent dose of prednisone of \> 20 mg daily for \>14 days), immunosuppressive anti-cancer, interleukins, systemic interferons, systemic chemotherapy or other medications considered significant by the trial physician within the last 12 weeks.
* History of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis in the 2 years prior to enrollment.
* History of chronic urticaria requiring current daily treatment.
* Known history of active Hepatitis B or Hepatitis C infection. \[NOTE: Participant is eligible if hepatitis C virus (HCV) cure or clearance is documented.\]
* History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, including a previous diagnosis of any of the following:
* Acute myocardial infarction
* Acute coronary syndromes
* Stable or unstable angina
* Coronary or other arterial revascularization
* Stroke
* Transient ischemic attack
* Peripheral arterial disease presumed to be of atherosclerotic origin
* Any history of receipt of HIV vaccine candidate or HIV-specific monoclonal antibody therapy.
* Participation in any clinical study of an investigational product within 28 days prior to study entry (day 0) or expected participation in such a study during participation in this study. \[NOTE: Treatment or receipt of prophylaxis against other infectious pathogens such as SARS-CoV-2 or Monkeypox under Emergency Use Authorization within 28 days of study entry is not exclusionary.\]
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Breastfeeding
* Laboratory abnormalities in the parameters listed below, obtained by any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate EQA programs.
* Absolute neutrophil count \<750 cells/mm3
* Hemoglobin \<9 gm/dL for volunteers who were assigned female sex at birth, \<10.0 g/dL for volunteers who were assigned male sex at birth
* Platelet count \<100,000 cells/mm3
* ALT \>3 x ULN
* AST \>3 x ULN
* Total bilirubin \>2 x ULN
* eGFR \<60 mL/min/1.73m2
* Use of prohibited medications with ART within 7 days prior to study entry, or planned use of prohibited medications during the period of study participation.
\[NOTE: Use of St. John's wort within 7 days prior to study entry is acceptable but must be discontinued on the day of study entry\]
* Viral failure after Step 1 week 24.
* Participant never started ART.
* Participant interrupted ART ≥7 consecutive days in Step 1.
* Current use of an ART regimen that includes a long-acting or NNRTI component.
* Intercurrent illness, new medical diagnosis, laboratory abnormality, sign, or symptom that, in the opinion of the site investigator, would place participant at higher risk of morbidity during ATI.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Transfer to A5385 (The Post-Intervention Cohort Study) \[NOTE: Participants may be offered co-enrollment or transfer to A5385, depending on ACTG identification of the preferred methodology for observation during extended ATI.\]
* Intercurrent illness, new medical diagnosis, laboratory abnormality, sign, or symptom that, in the opinion of the site investigator, would place participant at higher risk of morbidity during analytic treatment interruption.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* None
* Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the preceding 36 months or for whom such therapies are expected in the subsequent 12 months. \[NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) are not exclusionary.\]
* History of AIDS-defining illness within 3 years prior to enrollment.
* History of systemic corticosteroids (e.g., an equivalent dose of prednisone of \> 20 mg daily for \>14 days), immunosuppressive anti-cancer, interleukins, systemic interferons, systemic chemotherapy or other medications considered significant by the trial physician within the last 12 weeks.
* History of a severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis in the 2 years prior to enrollment.
* History of chronic urticaria requiring current daily treatment.
* Known history of active Hepatitis B or Hepatitis C infection. \[NOTE: Participant is eligible if hepatitis C virus (HCV) cure or clearance is documented.\]
* History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, including a previous diagnosis of any of the following:
* Acute myocardial infarction
* Acute coronary syndromes
* Stable or unstable angina
* Coronary or other arterial revascularization
* Stroke
* Transient ischemic attack
* Peripheral arterial disease presumed to be of atherosclerotic origin
* Any history of receipt of HIV vaccine candidate or HIV-specific monoclonal antibody therapy.
* Participation in any clinical study of an investigational product within 28 days prior to study entry (day 0) or expected participation in such a study during participation in this study. \[NOTE: Treatment or receipt of prophylaxis against other infectious pathogens such as SARS-CoV-2 or Monkeypox under Emergency Use Authorization within 28 days of study entry is not exclusionary.\]
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Breastfeeding
* Laboratory abnormalities in the parameters listed below, obtained by any Network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate EQA programs.
* Absolute neutrophil count \<750 cells/mm3
* Hemoglobin \<9 gm/dL for volunteers who were assigned female sex at birth, \<10.0 g/dL for volunteers who were assigned male sex at birth
* Platelet count \<100,000 cells/mm3
* ALT \>3 x ULN
* AST \>3 x ULN
* Total bilirubin \>2 x ULN
* eGFR \<60 mL/min/1.73m2
* Use of prohibited medications with ART within 7 days prior to study entry, or planned use of prohibited medications during the period of study participation.
\[NOTE: Use of St. John's wort within 7 days prior to study entry is acceptable but must be discontinued on the day of study entry\]
* Viral failure after Step 1 week 24.
* Participant never started ART.
* Participant interrupted ART ≥7 consecutive days in Step 1.
* Current use of an ART regimen that includes a long-acting or NNRTI component.
* Intercurrent illness, new medical diagnosis, laboratory abnormality, sign, or symptom that, in the opinion of the site investigator, would place participant at higher risk of morbidity during ATI.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Transfer to A5385 (The Post-Intervention Cohort Study) \[NOTE: Participants may be offered co-enrollment or transfer to A5385, depending on ACTG identification of the preferred methodology for observation during extended ATI.\]
* Intercurrent illness, new medical diagnosis, laboratory abnormality, sign, or symptom that, in the opinion of the site investigator, would place participant at higher risk of morbidity during analytic treatment interruption.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* None
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
collaborator
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Trevor Crowell, MD, PhD
Role: STUDY_CHAIR
US Military HIV Research Program CTU
Wadzanai Samaneka, MBChB, MSc
Role: STUDY_CHAIR
Milton Park CRS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gaborone CRS (12701)
Gaborone, , Botswana
Site Status
RECRUITING
University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)
Johannesburg, Gauteng, South Africa
Site Status
RECRUITING
CAPRISA eThekwini CRS (31422)
Durban, KwaZulu-Natal, South Africa
Site Status
RECRUITING
Durban Adult HIV CRS (11201)
Durban, , South Africa
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Botswana
South Africa
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACTG A5417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175
NCT00096824
COMPLETED
Suppression of HIV 1 RNA in People Living With HIV
NCT02363387
COMPLETED
NA
Immunologic Control of Drug Resistant HIV
NCT00053404
UNKNOWN
Liraglutide for HIV-associated Neurocognitive Disorder
NCT02743598
TERMINATED
PHASE4
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
NCT02624180
COMPLETED
PHASE2
Acute HIV Infection Observational Study
NCT00296660
COMPLETED
Long-term Follow-up of HIV Infected Patients Identified During Early Infection
NCT00086372
COMPLETED
HIV-1 Resistance at Screening for HIV Prevention Studies
NCT01204814
COMPLETED
A Study of the Long-Term Outcomes of HIV-Positive Patients
NCT00000932
COMPLETED
PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)
NCT03733093
COMPLETED
Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
NCT00326482
COMPLETED
Enhancement by Poly-ICLC During HIV-1 Infection
NCT02071095
COMPLETED
PHASE1/PHASE2
Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy
NCT00009256
COMPLETED
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
NCT00002044
COMPLETED
NA
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
NCT05419024
RECRUITING
PHASE2
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
NCT00001644
COMPLETED
PHASE1
An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts
NCT00000709
COMPLETED
PHASE3
Cardiovascular Prevention for Persons With HIV
NCT00982189
COMPLETED
NA
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
NCT01519141
COMPLETED
A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
NCT00001121
COMPLETED
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
NCT01227044
COMPLETED
PHASE2/PHASE3
Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV
NCT03296202
RECRUITING
Effects of Anti-HIV Therapy on Nervous System Function
NCT00432003
COMPLETED
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
NCT01976715
COMPLETED
A Study of HIV-Disease Development in Aging
NCT00006144
COMPLETED
PHASE2